Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines

Anticancer Research

Volumn 19, Issue 6 B, 1999, Pages 5423-5428

  Bahadori, Hamid R ^a   Rocha Lima, Caio Max S ^b   Green, Mark R ^b   Safa, Ahmad R ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

Breast cancer; CPT 11; Gemcitabine; Irinotecan; Small cell lung cancer

Indexed keywords

GEMCITABINE; IRINOTECAN;

ARTICLE; BREAST CANCER; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENTIATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CAMPTOTHECIN; CARCINOMA, SMALL CELL; DEOXYCYTIDINE; DRUG SYNERGISM; HUMANS; LUNG NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0033368083     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Hertel LW, Boder B, Kroin JS, Rinzel SM, Poore GA, Todd GC and Grindey GB: Evaluation of the antitumor activity of a (2′,2′-difluoro-2′-deoxycytidine). Cancer Res 50: 4417-4422, 1990.
2. Eckardt J, Eckhardt G, Villalona-Calero M, Drengler R and Von Hoff D: New anticancer agents in clinical development. Oncology 9: 1321-1331, 1995.
3. Anderson H, Lund B, Bach F, Thatcher N, Walling J and Hansen HH: Single agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1821-1826, 1994.
4. Cormier Y, Eisenhauer E, Muldal A, Gregg R, Ayoub J, Goss G, Stewart D, Tarasoff P and Wong D: Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC): a study of National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 5: 283-285, 1994.
5. Huang P, Chubb S, Hertel LW, Grindey GB and Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991.
6. Gandhi V, Legha J, Chen F, Hertel LW and Plunkett W: Excision of 2′,2′-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 56: 4453-4459, 1996.
7. Heinemann V, Schulz L, Issels RD and Plunkett W: Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22 (4 Suppl 11): 11-18, 1995.
8. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, Yokokura T, Sawada S, Miyasaka T and Mutai M: Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944-5947, 1987.
9. Kawato Y, Aonuma M, Hirota Y, Kuga H and Sato K: Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191, 1991.
10. Shimada Y, Rothenberg ML, Hilsenbeck SG, Burris HA III, Degen D and Von Hoff DD: Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units. Anticancer Drugs 5: 202-206, 1994.
11. Kawato Y, Furuta T, Aonuma M, Yasuoka T and Matsumoto K: Antitumor activity of a camptothecin derivative, CPT-11, against humor tumor xenografts in nude mice. Cancer Chemother Pharmacol 28: 192-198, 1991.
12. Tsuruo T, Matsuzaki T, Matsushita M, Saito H and Yokokura T: Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 21: 71-74, 1988.
13. Shimada Y, Yoshino M, Wakui A, Nakao I, Sakata Y, Kambe M, Taguchi T and Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 11: 909-913, 1993.
14. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LJ and Von Hoff DD: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14: 1128-1135, 1996.
15. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Negoro S, Nishioka M, Nakagawa K and Takada M: CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10: 1225-1229, 1992.
16. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N et al: A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20, 1992.
17. Look KY, Blessing JA, Levenback C, Kohler M, Chafe W and Roman LD: A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology study group. Gynecol Oncol 70: 334-338, 1998.
18. Takeuchi S, Dobashi K, Fujimoto S, Tanaka K, Suzuki M, Terashima Y, Hasumi K, Akiya K, Negishi Y, Tamaya T, et al: A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Jpn J Chemother 18: 1681-1689, 1991.
19. Fleming GF, Amato JM, Agresti M and Safa AR: Megestrol acetate reverses multidrug resistance and interacts with P-glycoprotein. Cancer Chemother Pharmacol 29: 445-459, 1992.
20. Berenbaum MC: What is synergy? Pharmacol Rev 41: 93-141, 1990.
21. Chou T-C and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
22. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D and Rugg TA: Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12: 1535-1540, 1994.
23. Gatzemeier U, Shepherd FA, Le Chevalier T, Weynants P, Cottier B, Groen HJ, Rosso R, Mattson K, Cortes-Funes H, Tonato M, Burkes RL, Gottfried M and Voi M: Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32: 243-248, 1996.
24. Lund B, Hansen OP, Theilade K, Hansen M and Neijt JP: Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86: 1530-1533, 1994.
25. Carmichael J, Possinger K, Philip P, Beykirch M, Kerr H, Walling J and Harris AL: Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 13: 2731-2736, 1995.
26. Stadler WM, Kuzel T, Roth B, Raghavan D and Dorr FA: Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. J Clin Oncol 15: 3394-3398, 1997.
27. Moore MJ, Tannock IF, Ernst DS, Huan S and Murray N: Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol 15: 3441-3445, 1997.
28. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B and Tarassoff PG: Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 12: 29-32, 1994.
29. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G and Blatter J: Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 73: 101-105, 1996.
30. Sakata Y, Shimada Y, Yoshino M, Kambe M, Futatsuki K, Nakao I, Ogawa N, Wakui A and Taguchi T: A late phase II study of CPT-11, irinotecan hydrochloride, in patients with advanced pancreatic cancer. CPT-11 study group on gastrointestinal cancer. Jpn J Cancer Chemother 21: 1039-1046, 1994.
31. Chabot GG: Clinical pharmacokinetics of irinotecan. Clin Pharmacokinet 33: 245-259, 1997
32. Abbruzzese JL: Phase I studies with the novel nucleoside analog gemcitabine. Semin Oncol 23: 24-31, 1996.
33. Kanzawa F and Saijo N: In vitro interaction between gemcitabine and other anticancer drugs using a novel three-dimensional model. Semin Oncol 24 (2 Suppl 7): S7-8-S7-16, 1997.